[ET Net News Agency, 13 September 2021] MicroPort Scientific Corporation (00853) said
Shanghai MicroPort Medical (Group) Co., Ltd. (Shanghai MicroPort), a subsidiary of the
company, has entered into an equity transfer agreement with Fujian 618 Industrial Equity
Investment Partnership (Limited Partnership)) and Fujian Tendering and Procurement Group
Co., Ltd. (together, the vendors), under which Shanghai MicroPort as the strategic
investor, will acquire from the vendors 45% of the equity interests in Fujian Kerui
Pharmaceutical Co., Ltd. (Kerui Pharmaceutical) at the consideration of approximately
RMB111 million.
Upon completion of the transaction, Shanghai MicroPort will become the single largest
shareholder of Kerui Pharmaceutical. Shanghai MicroPort will also, through contractual
arrangement, obtain the control of the daily operation of Kerui Pharmaceutical.
Kerui Pharmaceutical is a national high-tech enterprise engaged in the research and
development, production and sales of high-value-added fermentation-based active
pharmaceutical ingredients (APIs) such as immunosuppressants and anti-tumour agents. (RC)